Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Changes associated with lenalidomide treatment in the gene expression profiles of patients with del(5q)

M. Belickova, J. Cermak, M. Dostalova Merkerova, J. Vesela, Z. Krejcik, E. Cechova, Z. Zemanova, K. Michalova, H. Votavova, M. Caniga, R. Neuwirtova, A. Jonasova,

. 2012 ; 12 (5) : 375-383.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc13024430

Grantová podpora
NS9634 MZ0 CEP - Centrální evidence projektů

UNLABELLED: We used microarray profiling to investigate the direct effects of lenalidomide on gene expression in isolated CD14(+) monocytes from 6 patients with del(5q). Our data demonstrate that changes in genes involved the tumor necrosis factor (TNF) signaling pathway and the bone marrow stroma, suggesting that treatment with lenalidomide may help restore the damaged niche and suppress the TNF signaling pathway. BACKGROUND: Lenalidomide is an effective treatment for patients with del(5q) and myelodysplastic syndrome (MDS) The exact mechanism of lenalidomide function and its impact on the prognosis of patients is not known exactly. MATERIALS AND METHODS: We used gene expression profiling to study the effect of lenalidomide therapy in peripheral blood CD14(+) monocytes of 6 patients with del(5q) and MDS. RESULTS: After lenalidomide treatment, genes involved in the tumor necrosis factor (TNF) signaling pathway that were upregulated in the patients before treatment decreased to the healthy control baseline expression level. This change in gene expression, in conjunction with increased expression of repressed genes that affect the stem cell niche (ie, CXCR4 and CRTAP), may exert a positive effect on treated patients. In contrast, we found that increased expression of the ARPC1B gene may have a negative impact on the stability of patient remission. CONCLUSION: The observed changes in gene expression described here may contribute to the identification of pathways that are affected by lenalidomide, which may help to explain the effects of this drug.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13024430
003      
CZ-PrNML
005      
20170110112125.0
007      
ta
008      
130703s2012 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.clml.2012.04.003 $2 doi
035    __
$a (PubMed)22608605
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Belickova, Monika $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. monika.belickova@uhkt.cz
245    10
$a Changes associated with lenalidomide treatment in the gene expression profiles of patients with del(5q) / $c M. Belickova, J. Cermak, M. Dostalova Merkerova, J. Vesela, Z. Krejcik, E. Cechova, Z. Zemanova, K. Michalova, H. Votavova, M. Caniga, R. Neuwirtova, A. Jonasova,
520    9_
$a UNLABELLED: We used microarray profiling to investigate the direct effects of lenalidomide on gene expression in isolated CD14(+) monocytes from 6 patients with del(5q). Our data demonstrate that changes in genes involved the tumor necrosis factor (TNF) signaling pathway and the bone marrow stroma, suggesting that treatment with lenalidomide may help restore the damaged niche and suppress the TNF signaling pathway. BACKGROUND: Lenalidomide is an effective treatment for patients with del(5q) and myelodysplastic syndrome (MDS) The exact mechanism of lenalidomide function and its impact on the prognosis of patients is not known exactly. MATERIALS AND METHODS: We used gene expression profiling to study the effect of lenalidomide therapy in peripheral blood CD14(+) monocytes of 6 patients with del(5q) and MDS. RESULTS: After lenalidomide treatment, genes involved in the tumor necrosis factor (TNF) signaling pathway that were upregulated in the patients before treatment decreased to the healthy control baseline expression level. This change in gene expression, in conjunction with increased expression of repressed genes that affect the stem cell niche (ie, CXCR4 and CRTAP), may exert a positive effect on treated patients. In contrast, we found that increased expression of the ARPC1B gene may have a negative impact on the stability of patient remission. CONCLUSION: The observed changes in gene expression described here may contribute to the identification of pathways that are affected by lenalidomide, which may help to explain the effects of this drug.
650    _2
$a komplex proteinů 2-3 souvisejících s aktinem $x genetika $x metabolismus $7 D051376
650    _2
$a senioři $7 D000368
650    _2
$a lipopolysacharidové receptory $x krev $x genetika $x metabolismus $7 D018950
650    _2
$a studie případů a kontrol $7 D016022
650    12
$a chromozomální delece $7 D002872
650    12
$a lidské chromozomy, pár 5 $7 D002895
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a exprese genu $x účinky léků $7 D015870
650    _2
$a lidé $7 D006801
650    _2
$a interleukin-1beta $x genetika $x metabolismus $7 D053583
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a monocyty $x účinky léků $x metabolismus $7 D009000
650    _2
$a myelodysplastické syndromy $x farmakoterapie $x genetika $x metabolismus $7 D009190
650    _2
$a prognóza $7 D011379
650    _2
$a protoonkogenní proteiny c-jun $x genetika $x metabolismus $7 D016755
650    _2
$a signální transdukce $x účinky léků $x genetika $7 D015398
650    _2
$a nika kmenových buněk $x účinky léků $x genetika $7 D055153
650    _2
$a thalidomid $x analogy a deriváty $x terapeutické užití $7 D013792
650    _2
$a transkriptom $x účinky léků $7 D059467
650    _2
$a TNF-alfa $x genetika $x metabolismus $7 D014409
650    _2
$a upregulace $x účinky léků $x genetika $7 D015854
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Cermak, Jaroslav $u -
700    1_
$a Dostalova Merkerova, Michaela $u -
700    1_
$a Veselá, Jitka $u - $7 xx0209625
700    1_
$a Krejcik, Zdenek $u -
700    1_
$a Cechova, Eliska $u -
700    1_
$a Zemanova, Zuzana $u -
700    1_
$a Michalova, Kyra $u -
700    1_
$a Votavova, Hana $u -
700    1_
$a Caniga, Miroslav $u -
700    1_
$a Neuwirtova, Radana $u -
700    1_
$a Jonasova, Anna $u -
773    0_
$w MED00180199 $t Clinical lymphoma, myeloma & leukemia $x 2152-2669 $g Roč. 12, č. 5 (2012), s. 375-383
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22608605 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20130703 $b ABA008
991    __
$a 20170110112222 $b ABA008
999    __
$a ok $b bmc $g 988110 $s 822810
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 12 $c 5 $d 375-383 $i 2152-2669 $m Clinical lymphoma, myeloma & leukemia $n Clin Lymphoma Myeloma Leuk $x MED00180199
GRA    __
$a NS9634 $p MZ0
LZP    __
$a Pubmed-20130703

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...